Abstract:
Objective To investigate the effect of dexmedetomidine on plasma levels of brain derived nerve growth factor (BDNF) and cognitive dysfunction in patients with meningioma.
Methods A total of 120 patients with meningioma were randomly divided into control group (normal saline) and observation group (dexmedetomidine), with 60 cases in each group. Mean arterial pressure (MAP), blood oxygen saturation (SpO2), heart rate (HR), and respiratory rate at 12 h (T3), 48 h (T4), 3 d (T5) and 7 d (T6) after extubation were compared between the two groups. BDNF changes at 30 min of intubation (T2), T3, T4, T5 and T6 in the two groups were statistically analyzed. The cognitive function changes of the two groups were evaluated before operation (T1), 8 d (T7), 14 d (T8), 20 d (T9), 24 d (T10), and 1 month (T11) of extubation.
Results The MAP and HR in the observation group were significantly lower than those in the control group at T3, T4, T5 and T6 (P < 0.05). Compared with T2, BDNF levels were significantly increased at T4 and T5 in the two groups (P < 0.05); the T6 BDNF level in the observation group was significantly increased, and was significantly higher than that in the control group (P < 0.05). Compared with T1, the Mini-Mental State Examination (MMSE) scores and Montreal Cognitive Assessment (MoCA) scores at time points from T7 to T11 in the control group were significantly decreased (P < 0.05); the MMSE and MoCA scores significantly decreased at time points from T7 to T9, and the MMSE as well as MOCA scores significantly increased at T10 and T11 in the observation group (P < 0.05). The MMSE and MoCA scores at T10 and T11of the observation group were significantly higher than those of the control group (P < 0.05).
Conclusion Dexmedetomidine has a good sedative effect in neurosurgery and can significantly improve the cognitive function of patients.